Plus therapeutics receives $1.9 million advance payment from cprit and plans to present at the cprit innovations in cancer prevention and research conference

Austin, texas, sept. 11, 2023 (globe newswire) -- plus therapeutics, inc. (nasdaq:  pstv ) (the “company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the company will present data from its respect-lm clinical trial evaluating the company's lead radiotherapeutic, rhenium (186re) obisbemeda, for the treatment of leptomeningeal metastases at the cancer prevention & research institute of texas (cprit) innovations in cancer prevention and research conference vi. the conference is taking place october 2-3, 2023, in galveston, tex. the poster presentation is titled, report of phase 1 part a of the respect-lm trial: rhenium (186re) obisbemeda (186rnl) in leptomeningeal metastases (lm) .
PSTV Ratings Summary
PSTV Quant Ranking